Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

BACKGROUND: Tumor mutational burden (TMB) is a significant predictor of immune checkpoint inhibitors (ICIs) efficacy. This study investigated the correlation between deep learning radiomic biomarker and TMB, including its predictive value for ICIs treatment response in patients with advanced non-sma...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: He, Bingxi, Dong, Di, She, Yunlang, Zhou, Caicun, Fang, Mengjie, Zhu, Yongbei, Zhang, Henghui, Huang, Zhipei, Jiang, Tao, Tian, Jie, Chen, Chang
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Immunotherapy Biomarkers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7342823/
https://ncbi.nlm.nih.gov/pubmed/32636239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000550
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars